Timing and number of new drugs launched in Canada on par with other countries
OTTAWA, April 11, 2017 /CNW/ - The Patented Medicine Prices Review Board (PMPRB), through the National Prescription Drug Utilization Information System (NPDUIS) research initiative, today published the first edition of Meds Entry Watch, a new annual
This edition provides a benchmark analysis of the international availability, launch sequence, market uptake, sales, and prices of new drugs introduced to Canadian and select international markets from 2009 to 2014, and offers a preliminary analysis of drugs launched in 2015.
The study found that high-priced, so-called "specialty drugs" are increasingly dominating the new drug landscape in Canada and internationally. Results also show that the drugs that account for the vast majority of new drug sales internationally over the time period studied are available in Canada. Moreover, the average time between a drug's launch in its country of origin and its entry onto the Canadian market is well within the timelines observed in the United States (US) and Europe. In fact, many new drugs enter the Canadian market second only to the US. Whereas the prices of new drugs in Canada are also generally in line with those observed in the European markets analyzed—and considerably below those in the US—foreign prices declined relative to Canadian levels over time.
Meds Entry Watch is available on the PMPRB website in PDF and accessible HTML formats.
Follow us on Twitter: @PMPRB_CEPMB
SOURCE Patented Medicine Prices Review Board
Subscribe to our Free Newsletters!